Kobayashi Kako controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile1 entries
2021
Kobayashi Kako admits drug manufacturing irregularities
Hazard disclosure
Kobayashi Kako admitted that irregular operations led to a key ingredient in oral antifungal medicines being replaced with a sleep-inducing ingredient, at 2.5 times Japan's maximum limit. The article also reports that more than 200 patients experienced health problems after taking the company's medicines.
Source excerpt
累计已有200多名患者在服用该公司药品后出现不同程度的健康受损。
小林化工承认，由于一系列违规操作，其制造的治疗脚癣等病的口服抗真菌药中，原本应该加入的一种主要成分被错误地替换成了睡眠诱导剂成分，而且睡眠诱导剂的添加量还达到了日本最高限量的2.5倍。
当地政府在近日对其下达了长达116天的停业整顿要求